KCNJ8 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2128828	1.00	17/20
SCHEMBL1289338	0.57	17/20
SCHEMBL1002731	0.73	15/20
SCHEMBL2450848	0.53	14/20
SCHEMBL561467	0.62	13/20
SCHEMBL562109	0.62	13/20
Zd-6169 (SCHEMBL2123811)	1.00	12/20
SCHEMBL2449485	0.50	11/20
SCHEMBL2123812	0.59	10/20
SCHEMBL2782571	0.37	10/20
SCHEMBL2783309	0.37	10/20
SCHEMBL589730	0.56	9/20
SCHEMBL2783558	0.39	9/20
SCHEMBL2129487	1.00	8/20
SCHEMBL2129489	1.00	8/20
SCHEMBL2782869	0.39	8/20
SCHEMBL2783508	0.38	8/20
SCHEMBL2783300	0.37	8/20
SCHEMBL2448630	0.53	7/20
SCHEMBL2451148	0.53	7/20

Clinical trials — most relevant to KCNJ8 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR)	PHASE4	UNKNOWN
Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes	PHASE4	COMPLETED
Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study	PHASE4	COMPLETED
Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels	PHASE3	COMPLETED
Renal Transplantation and Inhaled Anesthetic Sevoflurane (SEVOREIN)	PHASE3	COMPLETED
Evaluation of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2)	PHASE2/PHASE3	RECRUITING
Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation	PHASE3	COMPLETED
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
Evaluating Possible Improvement in Tinnitus Severity After 28 Days Dosing of the Study Drug AUT00063 Compared to Placebo	PHASE2	COMPLETED
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss	PHASE2	COMPLETED
Sandostatine® LP and Hyperinsulinism	PHASE2	COMPLETED
Efficacy and Safety Study of Sulfonylureas in Neonatal Diabetes Mellitus	PHASE2	COMPLETED
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK	PHASE1	COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
Regulation of KATP Channels and Na+/K+ ATPase in Relation to Fatigue Development	nan	COMPLETED
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	nan	UNKNOWN
Characteristics of Andersen-Tawil Syndrome	nan	COMPLETED
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)	nan	UNKNOWN
Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome	nan	RECRUITING
Feasibility of Improving Risk Stratification in Brugada Syndrome	nan	COMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Effect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura (ILIM)	nan	COMPLETED
Genetic Study for Infantile Onset Diabetes Mellitus	nan	UNKNOWN
The Use of Antiarrhythmic Drugs in Pediatrics	nan	UNKNOWN
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Interaction of Potassium and Genetic Risk Variants on Diabetes Risk	nan	COMPLETED
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
Safety of Oral Resin for Treatment of Hyperkalemia in Chinese Patients With Renal Insufficiency	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a KCNJ8 binder may also engage these)

Protein	Name	Similarity
P97794	—	1.000	P97794 →
Q63664	—	1.000	Q63664 →
Q9NPI9	—	0.997	Q9NPI9 →
P52186	—	0.992	P52186 →
Q61743	—	0.992	Q61743 →
P63253	—	0.992	P63253 →
P35561	—	0.991	P35561 →
Q9MYY9	—	0.991	Q9MYY9 →
KCNJ11	ATP-sensitive inward rectifier potassium channel 11	0.990	landscape →
P52185	—	0.990	P52185 →
KCNJ2	Inward rectifier potassium channel 2	0.990	landscape →
O19182	—	0.990	O19182 →
Q9Z307	—	0.990	Q9Z307 →
P86046	—	0.990	P86046 →
Q9JHJ9	—	0.990	Q9JHJ9 →
Q64273	—	0.989	Q64273 →
O02822	—	0.988	O02822 →
O18839	—	0.988	O18839 →
P70673	—	0.988	P70673 →
P49656	—	0.988	P49656 →
P52191	—	0.987	P52191 →
O70617	—	0.987	O70617 →
F1NHE9	—	0.986	F1NHE9 →
Q4TZY1	—	0.986	Q4TZY1 →
O60928	—	0.985	O60928 →
Q9QZ65	—	0.985	Q9QZ65 →
P63250	—	0.984	P63250 →
P52192	—	0.983	P52192 →
KCNJ3	G protein-activated inward rectifier potassium channel 1	0.983	landscape →
E1BN00	—	0.983	E1BN00 →